About US
Contact us
>>Back
GSK adopts new transparency policy
- Publisher：
- Publication：2012/10/16
GlaxoSmithKline's (GSK) chief executive has announced a new transparency policy that will see the pharmaceutical company share detailed clinical trial data with the wider scientific community.
A newly formed independent panel of experts will review and approve requests from researchers to access the company's data in a move that Sir Andrew Witty claims will "help further scientific understanding".
Speaking at a Wellcome Trust meeting in London, GSK's chief executive said: "As a truly global healthcare company, I believe we have a responsibility to do all we can at GSK to use our resources, knowledge and expertise to help tackle serious global health challenges.
"We need to take a different approach - one focused on partnership, collaboration and openness."
The company hopes that other pharmaceutical giants will follow suit by making their own data available to researchers.
Sir Mark Walport, director of the Wellcome Trust, welcomed GSK's commitment to openness and collaboration, adding that real breakthroughs "are borne of scientists sharing their knowledge and learning from each other".